Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma that has been Completely Removed by Surgery

Clinical Trial Title

NRG-BN003: Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

National Clinical Trial Number:

NCT03180268

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have a newly diagnosed unifocal intracranial meningioma, gross totally resected, and histologically confirmed as WHO grade II based upon pathology findings at the enrolling institution.
  • Are registered within 180 days of the initial surgery.
  • Are 18 years of age or older.
  • Have not received previous radiotherapy to the scalp, cranium, brain, or skull base.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Ken Tatebe, MD

Contact Information

Rush Cancer Center Clinical Trials Office

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more